1
|
Platzer L, Orthmann N, Grozinger P, Hennigs A, Rippinger N, Wallwiener M, Rom J, Riedel F. Does music genre affect medical students’ performance in standardized laparoscopic exercises? Comparing exposure to rock, hip-hop, classic and mixed radio music at 70 decibels. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L.K. Platzer
- Universitätsklinikum Heidelberg, Universitäts-Frauenklinik Heidelberg
| | - N. Orthmann
- Universitätsklinikum Heidelberg, Universitäts-Frauenklinik Heidelberg
| | - P. Grozinger
- Universitätsklinikum Heidelberg, Universitäts-Frauenklinik Heidelberg
| | - A. Hennigs
- Universitätsklinikum Heidelberg, Universitäts-Frauenklinik Heidelberg
| | - N. Rippinger
- Universitätsklinikum Heidelberg, Universitäts-Frauenklinik Heidelberg
| | - M. Wallwiener
- Universitätsklinikum Heidelberg, Universitäts-Frauenklinik Heidelberg
| | - J. Rom
- Klinikum Frankfurt-Höchst, Frauenklinik
| | - F. Riedel
- Universitätsklinikum Heidelberg, Universitäts-Frauenklinik Heidelberg
| |
Collapse
|
2
|
Koch KA, Reuner G, Beedgen B, Elsässer ML, Rom J, Fluhr H, Kölker S, Pöschl J, Sohn C, Unterberg A, Bächli H. Intrauterine Deckung von Myelomeningozelen. Monatsschr Kinderheilkd 2020. [DOI: 10.1007/s00112-019-0736-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
3
|
Rippinger N, Heinzler J, Bruckner T, Brucker J, Dinkic C, Hoffmann J, Dornhöfer N, Seitz S, Rom J, Sohn C, Schott TC, Schott S. The impact of a cervical dysplasia diagnosis on individual cancer prevention habits over time: a bicentric case-control study. Arch Gynecol Obstet 2019; 299:847-855. [PMID: 30607592 DOI: 10.1007/s00404-018-5029-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Accepted: 12/14/2018] [Indexed: 11/30/2022]
Abstract
PURPOSE Annual cervical cancer screening is recommended in Germany as a part of the statutory preventive care. Abnormal results can provoke psychological distress and anxiety, compromising women's adherence. Little is known about how a cervical dysplasia impacts adherence follow-up visits and prevention habits over time. To optimize care strategies, this study aims to identify women at risk for nonadherence to follow-up visits after a screening event. METHODS Between November 2015 and May 2017, participants with an abnormal Pap smear at the Heidelberg and Leipzig University Hospitals received a four-part questionnaire (sociodemographic data, PHQ-D, self-designed fear and prevention habit questions) at the first consultation (T1) and subsequently after 3 (T2) and 6 (T3) months; healthy controls completed the questionnaire at T1. RESULTS 132 women with an abnormal Pap smear [with conization: S1 (n = 68, 51.5%), without intervention: S2 (n = 64, 48.5%)] and healthy controls (K, n = 101) generally adhered to gynecological checkups, except S1 6 months after the first diagnosis (S1/T3 - 0.47, signed rank p < 0.0005). Knowledge of primary prevention information, i.e., HPV vaccination, was significantly higher among K (K 58%, S1 29%, S2 44%, Chi-squared p = 0.01) as was vaccine uptake (K 39% versus S1/S2 7% and 17%, respectively, Chi-squared p = 0.0004). Fear of upcoming Pap smears rose significantly over time (S1/T1-S1/T2-S1/T3, Wilcoxon signed-rank test p < 0.001) and was higher among those with conization at T2 (Chi-square test, p = 0.01) and partially accompanied by panic disorders at T1 (Chi-square test p = 0.035). Realization of general preventive habits rose significantly among women without an operative procedure (S2) over the study. CONCLUSION This study advances the understanding of non-participation in follow-up visits after a dysplasia diagnosis, identifying post-conization women as a special risk group for decreased adherence.
Collapse
Affiliation(s)
- N Rippinger
- Department of Gynaecology and Obstetrics, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - J Heinzler
- Department of Gynaecology and Obstetrics, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - T Bruckner
- Institute of Medical Biometry and Informatics (IMBI), University Hospital Heidelberg, Heidelberg, Germany
| | - J Brucker
- Department of Gynaecology and Obstetrics, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - C Dinkic
- Department of Gynaecology and Obstetrics, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - J Hoffmann
- Department of Gynaecology and Obstetrics, Leipzig University Hospital, Leipzig, Germany
| | - N Dornhöfer
- Department of Gynaecology and Obstetrics, Leipzig University Hospital, Leipzig, Germany
| | - S Seitz
- Department of Gynaecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany
| | - J Rom
- Department of Gynaecology and Obstetrics, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - C Sohn
- Department of Gynaecology and Obstetrics, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - T C Schott
- Department of Orthodontics and Orofacial Orthopedics, University Hospital Tubingen, Tubingen, Germany
| | - Sarah Schott
- Department of Gynaecology and Obstetrics, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany. .,German Cancer Consortium (DKTK), Heidelberg and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
| |
Collapse
|
4
|
Riedel F, Heil J, Golatta M, Schaefgen B, Hug S, Schott S, Rom J, Schuetz F, Sohn C, Hennigs A. Changes of breast and axillary surgery patterns in patients with primary breast cancer during the past decade. Arch Gynecol Obstet 2018; 299:1043-1053. [PMID: 30478667 DOI: 10.1007/s00404-018-4982-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Accepted: 11/16/2018] [Indexed: 12/17/2022]
Abstract
PURPOSE Breast-conserving therapy (BCT) is the standard procedure for most patients with primary breast cancer (BC). By contrast, axillary management is still under transition to find the right balance between avoiding of morbidity, maintaining oncological safety, and performing a staging procedure. The rising rate of primary systemic therapy creates further challenges for surgical management. METHODS Patients with primary, non-metastatic BC treated between 01.01.2003 and 31.12.2016 under guideline-adherent conditions were included in this study. For this prospectively followed cohort, breast and axillary surgery patterns are presented in a time-trend analysis as annual rate data (%) for several subgroups. RESULTS Overall, 6700 patients were included in the analysis. While BCT rates remained high (mean 2003-2016: 70.4%), the proportion of axillary lymph node dissection has declined considerably from 80.1% in 2003 to 16.0% in 2016, while the proportion for sentinel lymph node biopsy (SLND) has increased correspondingly from 10.3 to 76.4%. Among patients with cT1-2, cN0 breast cancer receiving BCT with positive SLND, the rate of axillary completion has decreased from 100% in 2008 to 24.4% in 2016. CONCLUSIONS In the past decade, SLNB has been established as the standard procedure for axillary staging of clinically node-negative patients. Surgical morbidity has been further reduced by the rapid implementation of new evidence from the ACOSOG Z0011 trial into clinical routine. The results reflect the transition towards more individually tailored, less invasive treatment for selected patient subgroups, especially in regards to axillary lymph node management.
Collapse
Affiliation(s)
- F Riedel
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - J Heil
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - M Golatta
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - B Schaefgen
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - S Hug
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - S Schott
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - J Rom
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - F Schuetz
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - C Sohn
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - A Hennigs
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
| |
Collapse
|
5
|
Riedel F, Orthmann N, Platzer L, Sohn C, Schütz F, Wallwiener M, Rom J. Evaluation des Einflusses von Musik unterschiedlicher Schalldruckpegel auf den Lerneffekt bei standardisierten laparoskopischen Übungsaufgaben – erste Ergebnisse einer Pilotstudie unter Medizinstudierenden an der Universitäts-Frauenklinik Heidelberg. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- F Riedel
- Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
| | - N Orthmann
- Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
| | - L Platzer
- Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
| | - C Sohn
- Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
| | - F Schütz
- Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
| | - M Wallwiener
- Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
| | - J Rom
- Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
| |
Collapse
|
6
|
Nees J, Schott S, Schafferer S, Müller U, Rom J, Tang Q, Koal T, Wolf B, Scheffler M, Marmé F, Sohn C, Schneeweiss A, Burwinkel B. Identification of a blood based metabolomic classifer for the detection of ovarian cancer – MeDOC. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Nees
- University Womens Clinic, Heidelberg, Deutschland
- Molecular Biology of Breast Cancer, University Womens Clinic, Heidelberg, Deutschland
| | - S Schott
- University Womens Clinic, Heidelberg, Deutschland
| | - S Schafferer
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - U Müller
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - J Rom
- University Womens Clinic, Heidelberg, Deutschland
| | - Q Tang
- Molecular Biology of Breast Cancer, University Womens Clinic, Heidelberg, Deutschland
- Molecular Epidemiology, C080, German Cancer Research Center, DKFZ, Heidelberg, Deutschland
| | - T Koal
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - B Wolf
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - M Scheffler
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - F Marmé
- National Center for Tumor Diseases, Heidelberg, Deutschland
| | - C Sohn
- University Womens Clinic, Heidelberg, Deutschland
| | - A Schneeweiss
- National Center for Tumor Diseases, Heidelberg, Deutschland
| | - B Burwinkel
- Molecular Biology of Breast Cancer, University Womens Clinic, Heidelberg, Deutschland
- Molecular Epidemiology, C080, German Cancer Research Center, DKFZ, Heidelberg, Deutschland
| |
Collapse
|
7
|
Nees J, Wejchert S, Bruckner T, Sohn C, Rom J, Schott S. Participation in cancer biobanking at a German department for obstetrics and gynecology. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Nees
- UFK, Heidelberg, Deutschland
| | | | - T Bruckner
- Institut für Medizinische Biometrie und Informatik, Heidelberg, Deutschland
| | - C Sohn
- UFK, Heidelberg, Deutschland
| | - J Rom
- UFK, Heidelberg, Deutschland
| | - S Schott
- UFK, Heidelberg, Deutschland
- DKTK, DKFZ, Heidelberg, Deutschland
| |
Collapse
|
8
|
Funk A, Schäfgen B, Heil J, Harcos A, Gomez C, Stieber A, Junkermann H, Hennigs A, Rauch G, Sinn HP, Riedel F, Hug S, Meier A, Schott S, Rom J, Schütz F, Sohn C, Golatta M. Evaluation des Nutzens von intraoperativer Präparateradiografie zur Randbeurteilung bei brusterhaltender Therapie maligner Brusttumore. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- A Funk
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - B Schäfgen
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - J Heil
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - A Harcos
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - C Gomez
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - A Stieber
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - H Junkermann
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - A Hennigs
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - G Rauch
- Institut für Medizinische Biometrie und Informatik, Heidelberg, Deutschland
| | - HP Sinn
- Institut für Pathologie und Neuropathologie, Heidelberg, Deutschland
| | - F Riedel
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - S Hug
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - A Meier
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - S Schott
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - J Rom
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - F Schütz
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - C Sohn
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| | - M Golatta
- Universitätsfrauenklinik Heidelberg, Heidelberg, Deutschland
| |
Collapse
|
9
|
Spratte J, Elsässer M, Pöschl J, Beedgen B, Lichtenstern C, Unterberg A, Bächli H, Rom J, Fluhr H, Sohn C. Erste Ergebnisse der offenen intrauterinen Operation der fetalen Spina bifida an der Universitäts-Frauenklinik Heidelberg. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Spratte
- Universitärtsklinikum Heidelberg, Universitätsfrauenklinik, Heidelberg, Deutschland
| | - M Elsässer
- Universitärtsklinikum Heidelberg, Universitätsfrauenklinik, Heidelberg, Deutschland
| | - J Pöschl
- Universitärtsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin, Heidelberg, Deutschland
| | - B Beedgen
- Universitärtsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin, Heidelberg, Deutschland
| | - C Lichtenstern
- Universitärtsklinikum Heidelberg, Anästhesiologische Klinik, Heidelberg, Deutschland
| | - A Unterberg
- Universitärtsklinikum Heidelberg, Neurochirurgische Klinik, Heidelberg, Deutschland
| | - H Bächli
- Universitärtsklinikum Heidelberg, Neurochirurgische Klinik, Heidelberg, Deutschland
| | - J Rom
- Universitärtsklinikum Heidelberg, Universitätsfrauenklinik, Heidelberg, Deutschland
| | - H Fluhr
- Universitärtsklinikum Heidelberg, Universitätsfrauenklinik, Heidelberg, Deutschland
| | - C Sohn
- Universitärtsklinikum Heidelberg, Universitätsfrauenklinik, Heidelberg, Deutschland
| |
Collapse
|
10
|
Schaefgen B, Heil J, Barr R, Radicke M, Harcos A, Gomez A, Stieber A, Andre H, Von Au A, Spratte J, Rauch G, Rom J, Schütz F, Sohn C, Golatta M. Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and tomosynthesis. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30694-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Lapert F, Schramm K, Hoffmann J, Eismann S, Rippinger N, Maatouk I, Rom J, Stepan H, Sohn C, Schott S. Notdienstkonsultationen in der Geburtsmedizin – Zeit für Telemedizin? Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1606166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- F Lapert
- Universitätsfrauenklinik Heidelberg; Heidelberg
| | - K Schramm
- Universitätsfrauenklinik Heidelberg; Heidelberg
| | - J Hoffmann
- Abteilung für Geburtsmedizin, Universitätsklinikum Leipzig, Leipzig
| | - S Eismann
- Universitätsfrauenklinik Heidelberg; Heidelberg
| | - N Rippinger
- Universitätsfrauenklinik Heidelberg; Heidelberg
| | - I Maatouk
- Klinik für Allgemeine Innere Medizin & Psychosomatik Universitätsklinikum Heidelberg
| | - J Rom
- Universitätsfrauenklinik Heidelberg; Heidelberg
| | - H Stepan
- Abteilung für Geburtsmedizin, Universitätsklinikum Leipzig, Leipzig
| | - C Sohn
- Universitätsfrauenklinik Heidelberg; Heidelberg
| | - S Schott
- Universitätsfrauenklinik Heidelberg; Heidelberg
| |
Collapse
|
12
|
Brecht L, Wallwiener M, Schott S, Domschke C, Dinkic C, Golatta M, Schuetz F, Fluhr H, Stenzinger A, Kirchner M, Sohn C, Rom J. Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1606228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- L Brecht
- St. Josef's Hospital, Department for internal medicine, Heidelberg
| | - M Wallwiener
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| | - S Schott
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| | - C Domschke
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| | - C Dinkic
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| | - M Golatta
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| | - F Schuetz
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| | - H Fluhr
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| | - A Stenzinger
- University of Heidelberg, Department of Pathology, Heidelberg
| | - M Kirchner
- University of Heidelberg, Institute of Medical Biometry and Informatics, Heidelberg
| | - C Sohn
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| | - J Rom
- University of Heidelberg, Department for Gynaecology and Obstetrics, Heidelberg
| |
Collapse
|
13
|
Heublein S, Au A, Michel L, Freis A, Rom J, Wallwiener M, Marmé F, Schütz F, Sohn C. Einführung eines individuellen Curriculums in der studentischen Lehre im Fach Gynäkologie und Geburtshilfe – ein Vorher-Nachher Vergleich an der Universitäts-Frauenklinik Heidelberg. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1606167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- S Heublein
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - A Au
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - L Michel
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - A Freis
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - J Rom
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - M Wallwiener
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - F Marmé
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - F Schütz
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - C Sohn
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| |
Collapse
|
14
|
Dinkic C, Eichbaum M, Schmidt M, Grischke EM, Gebauer G, Fricke HC, Lenz F, Wallwiener M, Marme F, Schneeweiss A, Sohn C, Rom J. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Gynecol Oncol 2017; 146:279-284. [PMID: 28528917 DOI: 10.1016/j.ygyno.2017.05.013] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Revised: 05/02/2017] [Accepted: 05/09/2017] [Indexed: 11/26/2022]
Abstract
PURPOSE The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy consisting of the investigational oral antiangiogenic agent pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, previously treated EOC. PATIENTS AND METHODS This study was designed as a multicenter phase I trial evaluating the optimal dose as well as activity and tolerability of pazopanib with metronomic cyclophosphamide in the treatment of patients with recurrent, platinum-resistant, previously treated ovarian, peritoneal, or fallopian tube cancer. Here, 50mg cyclophosphamide were combined with 400 to 800mg pazopanib daily. RESULTS Sixteen patients were treated; mean age was 66years. At dose levels (DL) I and II, one instance of dose-limiting toxicity (DLT) was seen in one of 6 patients. At DL III, two of four patients showed a DLT, leading to a maximum tolerated dose (MTD) of 600mg pazopanib daily. Median number of administered cycles was 6 (2-13), with three patients being treated for at least 13months. Median progression-free survival (PFS) and overall survival (OS) were 8.35months and 24.95months, respectively. 155 adverse events (AE) occurred, most frequently elevation of liver enzymes, leukopenia, diarrhea and fatigue. Altogether, five serious adverse events (SAE) developed in four patients. CONCLUSION Pazopanib 600mg daily p.o. and metronomic cyclophosphamide 50mg daily p.o. is a feasible regimen for patients with recurrent platinum-resistant EOC and showed promising activity in this previously treated patient population. TRIAL REGISTRATION Clin.trial.gov registry no.: NCT01238770.
Collapse
Affiliation(s)
- C Dinkic
- University of Heidelberg Medical School, Department of Gynecology and Obstetrics, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany.
| | - M Eichbaum
- HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Gynecologic Oncology, Ludwig-Erhard-Str. 100, 65199 Wiesbaden, Germany
| | - M Schmidt
- University of Mainz Medical School, Department of Gynecology and Obstetrics, Langenbeckstr. 1, 55131 Mainz, Germany
| | - E M Grischke
- University of Tuebingen Medical School, Department of Gynecology and Obstetrics, Calwerstraße 7, 72076 Tuebingen, Germany
| | - G Gebauer
- Klinik für Gynäkologie und gynäkologische Onkologie, Marienkrankenhaus Hamburg, Alfredstraße 9, 22087 Hamburg, Germany
| | - H C Fricke
- Frauenklinik Klinikum Konstanz, Luisenstraße 7, 78464 Konstanz, Germany
| | - F Lenz
- Frauenklinik Sankt-Marienkrankenhaus Ludwigshafen, Salzburger Straße 15, 67067 Ludwigshafen, Germany
| | - M Wallwiener
- University of Heidelberg Medical School, Department of Gynecology and Obstetrics, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany
| | - F Marme
- University of Heidelberg Medical School, Department of Gynecology and Obstetrics, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany
| | - A Schneeweiss
- University of Heidelberg Medical School, Department of Gynecology and Obstetrics, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany
| | - C Sohn
- University of Heidelberg Medical School, Department of Gynecology and Obstetrics, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany
| | - J Rom
- University of Heidelberg Medical School, Department of Gynecology and Obstetrics, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany
| |
Collapse
|
15
|
Heinzler J, Vetter L, Brucker J, Weimer K, Bruckner T, Rom J, Mayer C, Sohn C, Schott TC, Schott S. Beeinträchtigung der Sexualität von Frauen durch eine Konisation – erste Ergebnisse. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
16
|
Hennigs A, Riedel F, Gondos A, Sinn HP, Marmé F, Golatta M, Rom J, Schütz F, Sohn C, Heil J, Schneeweiss A. Ergebnisqualität von Brustkrebs-Subtypen in der klinischen Routine – eine große, prospektive Kohortenstudie. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
17
|
Mayer C, Schmidt M, Grischke EM, Gebauer G, Fricke HC, Lenz F, Bischofs E, Wallwiener M, Marme F, Schneeweiss A, Sohn C, Eichbaum M, Rom J. The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
18
|
Wejchert S, Dinkic C, Kulozik A, Sinn P, Sohn C, Rom J. 12-jähriges Mädchen mit nicht DES-assoziiertem klarzelligem Adenokarzinom der Cervix uteri – ein Fallbericht. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
19
|
Schott S, Heinzler J, Brucker J, Weimer K, Bruckner T, Rom J, Cohrs F, Mayer C, Sohn C, Schott TC, Schott S. Beeinträchtigung der Sexualität von Frauen durch eine Konisation und Einfluss auf gesundheitliche Versorgungsangebote – ein prospektives Monocenter-Studiendesign. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1571384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
20
|
Wallwiener M, Deutsch TM, Riethdorf S, Hartkopf AD, Taran FA, Trumpp A, Brucker S, Schütz F, Rom J, Pantel K, Schneeweiss A. Abstract P2-02-06: Impact of apoptotic circulating tumor cells in metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-02-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Circulating tumor cells (CTC) are a heterogeneous cell population and an independent negative prognostic factor for progression-free (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC). The study aimed to prospectively assess CTC status for the subtypes apoptotic CTC (aCTC) and intact CTC (iCTC) at baseline (CTCBL) and after one cycle of a new line of systemic therapy (CTC1C). Changes from CTCBL to CTC1C (CTC kinetics, CTCKIN) were evaluated for their utility in predicting response, progression-free (PFS) and overall survival (OS).
Methods
423 MBC patients were included in a prospective trial prior to a new regimen of treatment. Intact and apoptotic CTC were analyzed at baseline (CTCBL) and after one cycle of systemic therapy (CTC1C) using CellSearch™ (Veridex) and morphologic criteria. Samples with ≥5 CTC/7.5ml blood were regarded as positive. Therapy response was assessed using the RECIST-criteria on three-monthly radiological controls. CTCKIN were characterized by ≥25% change from CTCBL to CTC1C to differentiate stable, increased and decreased CTC kinetic.
Results
35% of patients were iCTCBL-positive and 28% aCTCBL-positive at baseline (CTCBL). PFS and OS differ significantly between the iCTCBL-positive and the iCTCBL-negative group (PFS 4.5 vs. 8.0; OS 12.5 vs. 27.2 (months)). Positive aCTC in conjunction with positive iCTCBL at baseline has worst prognostic impact (PFS 6.3; OS 8.7).
Regarding the CTCKIN (BL to 1C), aCTC-decrease (≥25%) is a positive prognostic factor compared to aCTC-stable and aCTC-increase (PFS 7.6 vs. 3.7; 3.3 and OS 21.0 vs. 4.8; 5.7). Decreasing aCTCKIN shows favorable prognostic impact versus decreasing iCTCKIN (PFS 7.6 vs. 5.9 and OS 21.0 vs 16.4).
Conclusion
Elevated aCTC levels at baseline have an unfavorable prognostic impact on both OS and PFS in conjunction with elevated iCTC. Additionally, the decrease of aCTC is a relevant prognostic value for systemic therapy response. aCTCKIN allows better differentiation for therapy response in patients with positive CTC-status at baseline. Differentiated enumeration of intact and apoptotic CTC should be considered in clinical application.
Citation Format: Wallwiener M, Deutsch TM, Riethdorf S, Hartkopf AD, Taran F-A, Trumpp A, Brucker S, Schütz F, Rom J, Pantel K, Schneeweiss A. Impact of apoptotic circulating tumor cells in metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-06.
Collapse
Affiliation(s)
- M Wallwiener
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - TM Deutsch
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Riethdorf
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - AD Hartkopf
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F-A Taran
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Trumpp
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Brucker
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Schütz
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Rom
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Pantel
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Schneeweiss
- University of Heidelberg, Heidelberg, Baden Württemberg, Germany; National Center for Tumor Diseases, Heidelberg, Baden Württemberg, Germany; University of Tuebingen, Tuebingen, Baden Württemberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Baden Württemberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
21
|
Arians N, Förster R, Uhl M, Rom J, Debus J, Lindel K. Outcome of Patients With Local Recurrent Gynecologic Malignancies After Resection Combined With Intraoperative Radiation. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
22
|
Rauh C, Schuetz F, Rack B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Heil J, Rom J, Sohn C, Andergassen U, Jueckstock J, Fehm T, Loehberg CR, Hein A, Schulz-Wendtland R, Hartmann A, Beckmann MW, Janni W, Fasching PA, Häberle L. Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients. Geburtshilfe Frauenheilkd 2015; 75:588-596. [PMID: 26166840 DOI: 10.1055/s-0035-1546149] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2015] [Revised: 05/02/2015] [Accepted: 05/19/2015] [Indexed: 12/23/2022] Open
Abstract
Introduction: Use of hormone therapy (HT) has declined dramatically in recent years. Some studies have reported that HT use before a diagnosis of breast cancer (BC) may be a prognostic factor in postmenopausal patients. This study aimed to examine the prognostic relevance of HT use before BC diagnosis. Methods: Four BC cohort studies in Germany were pooled, and 4492 postmenopausal patients with HT use data were identified. Patient data and tumor characteristics were compared between users and nonusers, along with overall survival (OS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Cox proportional hazards models were stratified by study center and adjusted for age at diagnosis, tumor stage, grading, nodal status, and hormone receptors. Results: Women with HT use before the diagnosis of BC were more likely to have a lower tumor stage, to be estrogen receptor-negative, and to have a lower grading. With regard to prognosis there were effects seen for OS, DMFS and LRFS, specifically in the subgroup of women with a positive hormone receptor. In these subgroups, BC patients had a better prognosis with previous HT use. Conclusions: HT use before a diagnosis of BC is associated with a more favorable prognosis in women with a positive hormone receptor status. It may be recommended that the prognostic factor HT should be documented and analyzed as a confounder for prognosis in studies of postmenopausal hormone-responsive breast cancers.
Collapse
Affiliation(s)
- C Rauh
- University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen
| | - F Schuetz
- Breast Unit, Department of Gynecology and Obstetrics, Heidelberg University Hospital
| | - B Rack
- Department of Gynecology and Obstetrics, Campus Innenstadt University Hospital, Ludwig Maximilian University, Munich
| | - E Stickeler
- Department of Obstetrics and Gynecology, Freiburg University Medical Center, Freiburg
| | - M Klar
- Department of Obstetrics and Gynecology, Freiburg University Medical Center, Freiburg
| | - M Orlowska-Volk
- Institute of Pathology, Freiburg University Medical Center, Freiburg
| | - M Windfuhr-Blum
- Department of Radiology, Freiburg University Medical Center, Freiburg
| | - J Heil
- Breast Unit, Department of Gynecology and Obstetrics, Heidelberg University Hospital
| | - J Rom
- Breast Unit, Department of Gynecology and Obstetrics, Heidelberg University Hospital
| | - C Sohn
- Breast Unit, Department of Gynecology and Obstetrics, Heidelberg University Hospital
| | - U Andergassen
- Department of Gynecology and Obstetrics, Campus Innenstadt University Hospital, Ludwig Maximilian University, Munich
| | - J Jueckstock
- Department of Gynecology and Obstetrics, Campus Innenstadt University Hospital, Ludwig Maximilian University, Munich
| | - T Fehm
- Department of Gynecology and Obstetrics, Duesseldorf University Hospital, Düsseldorf
| | - C R Loehberg
- University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen
| | - A Hein
- University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen
| | - R Schulz-Wendtland
- Institute of Diagnostic Radiology, University Breast Center, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen
| | - A Hartmann
- Institute of Pathology, University Breast Center, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen
| | - M W Beckmann
- University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen
| | - W Janni
- Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm
| | - P A Fasching
- University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen ; Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA
| | - L Häberle
- University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen ; Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen
| |
Collapse
|
23
|
Rom J, Brecht L, Schütz F, Domschke C, Schott S, Sohn C, Wallwiener M. Eigenschaften und Sicherheit der aktuellen endoskopischen Versiegelungs- und Schneideinstrumente. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
24
|
Thum J, Mayer C, Sohn C, Rom J. Evaluation der Sensibilität und Spezifität eines dynamischen digitalen Videokolposkops (DySIS – Dynamic Spectral Imaging System) bei zervikalen Präkanzerosen. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
25
|
Heil J, Gondos A, Rauch G, Marmé F, Rom J, Golatta M, Junkermann H, Sinn P, Aulmann S, Debus J, Hof H, Schütz F, Brenner H, Sohn C, Schneeweiss A. Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. Breast 2012; 21:303-8. [DOI: 10.1016/j.breast.2012.01.009] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2011] [Revised: 01/07/2012] [Accepted: 01/18/2012] [Indexed: 01/07/2023] Open
|
26
|
Heil J, Buehler A, Golatta M, Rom J, Schipp A, Harcos A, Schneeweiss A, Rauch G, Sohn C, Junkermann H. Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI? Ann Oncol 2012; 23:98-104. [PMID: 21460377 DOI: 10.1093/annonc/mdr064] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Breast magnetic resonance imaging (MRI) has been introduced in the preoperative management of invasive lobular breast cancer (ILC). We analysed if MRI leads to adequate changes in surgical management. PATIENTS AND METHODS We carried out a single-centre retrospective confirmatory analysis of 92 patients with ILC and a preoperative breast MRI. By applying a blinded tumour board method, we analysed if surgical procedures were altered due to breast MRI. In case of alteration, we analysed whether the change was adequate according to the postoperative pathology findings. We considered an adequate rate of change>5% to be a clinically relevant benefit. RESULTS A change in surgical therapy due to the MRI findings occurred in 23 of 92 patients (25%). According to the postoperative pathology findings, this change was adequate for 20 of these patients (22%; 95% confidence interval [CI] 14%-31%, P<0.0001). An overtreatment occurred for three patients (3%; 95% CI 0%-6%) who underwent a mastectomy following the results of breast MRI. Patients with larger tumours did likely benefit more from preoperative breast MRI. CONCLUSIONS Patients with ILC might benefit from a preoperative breast MRI. Possible harm from overtreatment should be minimised by diligent use of preoperative histological clarification.
Collapse
Affiliation(s)
- J Heil
- Breast Unit, Women's Hospital, Heidelberg.
| | - A Buehler
- Breast Unit, Women's Hospital, Heidelberg
| | - M Golatta
- Breast Unit, Women's Hospital, Heidelberg
| | - J Rom
- Breast Unit, Women's Hospital, Heidelberg
| | - A Schipp
- Department of Radiology, Heidelberg
| | - A Harcos
- Breast Unit, Women's Hospital, Heidelberg
| | | | - G Rauch
- Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
| | - C Sohn
- Breast Unit, Women's Hospital, Heidelberg
| | | |
Collapse
|
27
|
Kenngott HG, Fischer L, Nickel F, Rom J, Rassweiler J, Müller-Stich BP. Status of robotic assistance--a less traumatic and more accurate minimally invasive surgery? Langenbecks Arch Surg 2011; 397:333-41. [PMID: 22038293 DOI: 10.1007/s00423-011-0859-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Accepted: 10/05/2011] [Indexed: 10/15/2022]
Abstract
PURPOSE Robotic assistance is considered one innovation within abdominal surgery over the past decade that has the potential to compensate for the drawbacks of conventional laparoscopy, such as limited degree of freedom, 2D vision, fulcrum, and pivoting effect. Robotic systems provide corresponding solutions as 3D view, intuitive motion and enable additional degrees of freedom. This review provides an overview of the history of medical robotics, experimental studies, clinical state-of-the-art and economic impact. METHODS The Medline database was searched for the terms "robot, telemanipulat, and laparoscop." A total of 2,573 references were found. All references were considered for information on robotic assistance in advanced laparoscopy. Further references were obtained through cross-referencing the bibliography cited in each work. RESULTS In experimental studies, current robotic systems showed superior handling and ergonomics compared to conventional laparoscopic techniques. In gynecology especially for hysterectomy and in urology especially for prostatectomy, two procedures formerly performed via an open approach, the robot enables a laparoscopic approach. This results in reduced need for pain medication, less blood loss, and shorter hospital stay. Within abdominal surgery, clinical studies were generally unable to prove a benefit of the robot. While the benefit still remains open to discussion, robotic systems are spreading and are available worldwide in tertiary centers. CONCLUSION Robotic assistance will remain an intensively discussed subject since clinical benefits for most procedures have not yet been proven. The most promising procedures are those in which the robot enables a laparoscopic approach where open surgery is usually required.
Collapse
Affiliation(s)
- H G Kenngott
- Department of General, Abdominal and Transplant Surgery, Heidelberg University, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | | | | | | | | | | |
Collapse
|
28
|
Rom J, Schumacher C, Gluz O, Zuna I, Eidt S, Marmé F, Nitz U, Sohn C, Schneeweiss A. Bedeutung und Prognose des Her2/neu-Rezeptors in primären Mammakarzinomen <2cm (T1). Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
29
|
Sinn H, Elsawaf Z, Bermejo JL, Aulmann S, Rom J, Schneeweiss A. Basoluminal and luminal phenotypes in triple-negative breast cancer: Immunohistochemical profiling and survival. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Kleinsorge F, Smetanay K, Rom J, Hörmannsdörfer C, Scharf A, Schmidt P. Prospektive Testleistungsbewertung des Ersttrimester Screenings in Deutschland bei Risikoberechnung über http://www.firsttrimester.net. Z Geburtshilfe Neonatol 2011. [DOI: 10.1055/s-0031-1271803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Kleinsorge F, Smetanay K, Rom J, Hörmansdörfer C, Hörmannsdörfer C, Scharf A, Schmidt P. [Prospective performance evaluation of first trimester screenings in Germany for risk calculation through http://www.firsttrimester.net]. Z Geburtshilfe Neonatol 2011; 214:239-42. [PMID: 21207324 DOI: 10.1055/s-0030-1265199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND In 2008, 2 351 first trimester screenings were calculated by a newly developed internet database ( http:// www.firsttrimester.net ) to evaluate the risk for the presence of Down's syndrome. MATERIAL AND METHODS All data were evaluated by the conventional first trimester screening according to Nicolaides (FTS), based on the previous JOY Software, and by the advanced first trimester screening (AFS). After receiving the feedback of the karyotype as well as the rates of the correct positives, correct negatives, false positives, false negatives, the sensitivity and specificity were calculated and compared. RESULTS Overall 255 cases were investigated which were analysed by both methods. These included 2 cases of Down's syndrome and one case of trisomy 18. The FTS and the AFS had a sensitivity of 100%. The specificity was 88.5% for the FTS and 93.0% for the AFS. CONCLUSION As already shown in former studies, the higher specificity of the AFS is a result of a reduction of the false positive rate (28 to 17 cases). As a consequence of the AFS with a detection rate of 100% the rate of further invasive diagnostics in pregnant women is decreased by having 39% fewer positive tested women.
Collapse
Affiliation(s)
- F Kleinsorge
- Universitätsfrauenklinik Heidelberg, Vosstrasse 9, Heidelberg.
| | | | | | | | | | | | | |
Collapse
|
32
|
Schneeweiss A, Schumacher C, Gluz O, Zuna I, Eidt S, Marme F, Nitz U, Sohn C, Rom J. Association of HER2 overexpression and prognosis in small primary breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Rom J, von Minckwitz G, Marmé F, Ataseven B, Kozian D, Sievert M, Schlehe B, Schuetz F, Scharf A, Kaufmann M, Sohn C, Schneeweiss A. Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. Ann Oncol 2009; 20:1829-35. [PMID: 19605509 DOI: 10.1093/annonc/mdp208] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Expression of the Bcl-2 protein confers resistance to chemotherapy-mediated apoptotic signals in patients with breast cancer. We investigated effects of Bcl-2 down-regulation by the Bcl-2 antisense oligodeoxynucleotide oblimersen in breast tumor biopsies. Oblimersen targets Bcl-2 messenger RNA (mRNA), down-regulates Bcl-2 protein translation and enhances antitumor effects of subtherapeutic chemotherapy doses. Within a phase I trial, we administered escalating doses of oblimersen (3, 5 or 7 mg/kg/day) as continuous infusion on days 1-7 in combination with standard-dose docetaxel (Taxotere), Adriamycin and cyclophosphamide (TAC) on day 5 as preoperative chemotherapy in 28 patients with T2-4 tumors. Effects of oblimersen were evaluated in tumor biopsies and peripheral blood mononuclear cells (PBMCs) 4 days after start of oblimersen and before TAC treatment by quantitative microfluidic real-time PCR. Read-outs consisted in measurement of Bcl-2 mRNA modulations and of 18 putative predictive markers. Two of 13 patients showed a diminution of Bcl-2 transcripts after 4 days of treatment with oblimersen 5 mg/kg/day. PBMCs could not be evaluated as a surrogate tissue because no qualified RNA could be isolated. Nevertheless, we demonstrated feasibility to process clinical samples and to obtain good quality RNA from tumor biopsies and indicated the potential of oblimersen to lower Bcl-2 mRNA in breast cancer.
Collapse
Affiliation(s)
- J Rom
- Department of Gynecology and Obstetrics, University of Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Rom J, von Minckwitz G, Marme F, Sievert M, Kozian D, Schuetz F, Scharf A, Kaufmann M, Sohn C, Schneeweiss A. Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e11576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11576 Background: The expression of the Bcl-2 protein confers resistance to chemotherapy mediated apoptotic signals in patients with breast cancer. The development of chemo sensitizing drugs may result in new treatment options. We investigated the effects of Bcl-2 down-regulation by the Bcl-2 antisense oligodeoxynucleotide oblimersen in breast tumor biopsies. Oblimersen targets Bcl-2 mRNA, thereby down regulates Bcl-2 protein translation, and enhances the antitumor effects of sub therapeutic doses of docetaxel. Methods: Within a phase I trial we administered escalating doses of oblimersen (3/5/7mg/kg/day) as continuous infusion on day 1–7 in combination with standard dosed docetaxel, doxorubicin, cyclophosphamide (TAC) on day 5 as preoperative chemotherapy in 28 patients with T2–4 breast cancers. Effects of oblimersen were evaluated in tumor biopsies and peripheral blood mononuclear cells (PBMCs) 4 days after start of oblimersen continuous infusion and before TAC treatment by quantitative microfluidic real-time polymerase chain reaction (RT-PCR). Read-outs consisted in measurement of Bcl-2 mRNA modulations and of 18 other putative predictive markers. Results: Two out of 13 patients showed a diminution of Bcl-2 transcripts after 4 days of treatment with oblimersen 5 mg/kg/day. PBMCs could not be evaluated as a surrogate tissue, because no qualified RNA could be isolated. Conclusions: Nevertheless, we demonstrated the feasibility to process clinical samples and to obtain good quality RNA from tumor biopsies, and indicated the potential of oblimersen to lower Bcl-2 mRNA in breast cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Rom
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - G. von Minckwitz
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - F. Marme
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - M. Sievert
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - D. Kozian
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - F. Schuetz
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - A. Scharf
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - M. Kaufmann
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - C. Sohn
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| | - A. Schneeweiss
- University Women's Hospital of Heidelberg, Heidelberg, Germany; University of Frankfurt, Frankfurt, Germany; Sanofi-Aventis GmbH, Berllin, Germany
| |
Collapse
|
35
|
Lenz FP, Scharf A, Sohn C, Rom J. Evaluierung einer deutschen Version des P-QOL Fragebogens bei Senkungszuständen. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1088916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
36
|
Lenz FP, Doll S, Sohn C, Rom J. Anatomische Lage verschiedener transobturieller Netzimplantate beim weiblichen Genitaldescensus im vorderen Kompartiment – Anatomische Beschreibung am Frischleichenpräparat. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1088576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
37
|
Rom J, von Minckwitz G, Eiermann W, Sievert M, Schlehe B, Marmé F, Schuetz F, Scharf A, Eichbaum M, Sinn HP, Kaufmann M, Sohn C, Schneeweiss A. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Ann Oncol 2008; 19:1698-705. [PMID: 18477581 DOI: 10.1093/annonc/mdn280] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Combining the Bcl-2 down-regulator oblimersen with cytotoxic treatment leads to synergistic antitumor effects in preclinical trials. This multicentric phase I study was carried out to evaluate maximum tolerated dose (MTD), safety and preliminary efficacy of oblimersen in combination with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment (NST) in primary breast cancer (PBC). METHODS Previously untreated patients with PBC T2-4a-c N0-3 M0 received one cycle of docetaxel 75 mg/m(2), adriamycin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) administered on day 5 combined with escalating doses of oblimersen as a 24-h continuous infusion on days 1-7 followed by five cycles of combination of docetaxel, adriamycin and cyclophosphamide (TAC) without oblimersen every 3 weeks. Prophylactic antibiotic therapy and granulocyte colony-stimulating factor administration were used in all six cycles. Blood serum samples were taken throughout the treatment period for pharmacokinetic analysis. RESULTS Twenty-eight patients were enrolled (median age, 50 years; ductal-invasive histology, 68%; tumorsize 2-5 cm, 61%; grade 3, 43%; hormone receptor negative, 36%; Her2 positive 18%) and received oblimersen in a dose of 3 mg/kg/day (cohort I, nine patients), 5 mg/kg/day (cohort II, nine patients) and 7 mg/kg/day (cohort III, 10 patients) respectively. No dose-limiting toxicity occurred. Following oblimersen combined with TAC, the most severe toxicity was neutropenia [National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grades 1-2/3/4] which developed in 0/0/56% of patients (cohort I), 11/0/56% of patients (cohort II) and 20/20/50% of patients (cohort III). No febrile neutropenia occurred. Most common adverse events (all NCI-CTC grade < or = 2) were fatigue, nausea, alopecia, headache and flue-like symptoms observed in 78% (cohort I), 89% (cohort II) and 90% (cohort III) of patients. With increasing dose of oblimersen, a higher incidence of grade IV leukopenia and neutropenia was noted. At the MTD of 7 mg/kg/day of oblimersen, serious adverse events occurred in 40% of the patients. CONCLUSION Oblimersen up to a dose of 7 mg/kg/day administered as a 24-h infusion on days 1-7 can be safely administered in combination with standard TAC on day 5 as NST in patients with PBC. The safety and preliminary efficacy warrants further evaluation of oblimersen in combination with every cycle of the TAC regimen in a randomized trial.
Collapse
Affiliation(s)
- J Rom
- Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Sch¨tz F, Beckhove P, Schneeweiss A, Rom J, Schirrmacher V, Sohn C. O-81 Interactions of tumorantigen-reactive T-cells derived from bone marrow and tumor-cells in breast cancer patient. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71771-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
39
|
Marmé F, Rom J, Schütz F, Eichbaum M, Sinn P, Sohn C, Schneeweiss A. HER2 overexpression is associated with shorter disease-free survival (DFS) following neoadjuvant systemic therapy (NST) of primary breast cancer (PBC) patients with gemcitabine (G), epirubicin (E) and docetaxel (Doc). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11087 Background: To evaluate prognostic factors for disease-free survival (DFS) following NST with G, E and Doc of patients with PBC. Methods: From 1/02 to 12/04 113 patients with T2–4 N0–2 M0 PBC received either six cycles of GEDoc (G 800 mg/m2 day (d) 1+8, E 60–90 mg/m2 d 1, Doc 60–75 mg/m2 d 1 every three weeks; 63 patients) or five cycles of GE (1,250 mg/m2 d 1, E 90–100 mg/m2 d 1 every two weeks) sequentially followed by four cycles of Doc (80–100 mg/m2 d 1every two weeks) with prophylactic filgrastim. 71% of tumours were hormone receptor positive, 24% HER2 positive (3+ by immunohistochemistry), 46% grade 3. 28 patients (25%) achieved a pathologic complete response (pCR) defined as no invasive tumour residue in the removed breast tissue at surgery. 9 of these patients had non-invasive cancer residues in the breast, one patient showed persisting axillary lymph node involvement. Results: With a median follow up of 3.2 years there is no statistically significant difference in DFS, distant DFS (DDFS) and overall survival (OS) rates between patients with and without pCR (DFS 79 versus (vs) 81 %, p=0,61; DDFS 82 vs 84 %, p=0.69; OS 86 vs 91%, p=0.33). In a Cox proportional hazards model HER2 3+ before NST (hazard ratio (HR)= 4.7; 95% confidence interval (CI) 1.9 - 11.3; p=0.0006), positive hormone receptors before NST (HR=0.27; 95% CI 0.11 - 0.65; p=0.003) and clinically nodal involvement before NST (HR=3.3; 95% CI 1.2–9.1; p=0.02) were statistically significant prognostic factors for recurrence whereas tumour size and grade before NST, the achievement of pCR, nodal status at surgery and response after 6 weeks of NST did not reach statistical significance. Thus far, in multivariate analysis only Her2 3+ before NST retained its prognostic significance (HR= 2.8; 95% CI 1.03 - 7.5, p=0.04). Conclusions: With a median follow-up of 3.2 years in multivariate analysis only HER2 3+ is associated with shorter DFS following NST containing G, E and Doc for PBC. Thus far, there is no statistically significant prognostic value for pCR. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Marmé
- University of Heidelberg, Heidelberg, Germany
| | - J. Rom
- University of Heidelberg, Heidelberg, Germany
| | - F. Schütz
- University of Heidelberg, Heidelberg, Germany
| | - M. Eichbaum
- University of Heidelberg, Heidelberg, Germany
| | - P. Sinn
- University of Heidelberg, Heidelberg, Germany
| | - C. Sohn
- University of Heidelberg, Heidelberg, Germany
| | | |
Collapse
|
40
|
Rom J, Schlehe B, Marmé F, Schuetz F, Eichbaum M, Sinn H, Buechele T, Sohn C, von Minckwitz G, Schneeweiss A. Oblimersen (O) in combination with docetaxel (T), adriamycin (A), and cyclophosphamide (C) as neoadjuvant systemic therapy (NST) in primary breast cancer (PBC): Final results of a multicentric phase I study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11047 Background: The Bcl-2 downregulator O in combination with standard cytotoxic chemotherapy leads to synergistic antitumor effects in preclinical trials. To evaluate maximum tolerated dose (MTD), safety and preliminary efficacy of O in combination with TAC as NST in PBC we performed a multicentric phase I study. Methods: Previously untreated patients with PBC T2–4a-c N0–3 M0 received escalating doses of O as a 24 hour continuous infusion on day (d) 1–7 in combination with T 75mg/m2, A 50mg/m2 and C 500 mg/m2 on day 5 followed by five three weekly cycles of TAC without O. Results: A total of twenty-eight patients with a median age of 50 years were enrolled. 61% of tumors were T2, 43% grade 3, 68% ductal-invasive, and 64% hormone receptor positive. Patients received O in a dose of 3 mg/kg/d (cohort I, 9 patients), 5 mg/kg/d (II, 9 patients), and 7 mg/kg/d (III, 10 patients), respectively. No dose-limiting toxicity occurred. Most common adverse events [all National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade = 2] were fatigue, nausea, alopecia, headache and flue-like symptoms observed in 78% (I), 89% (II), and 90% (III) of patients, respectively. Following OTAC the most severe hematological toxicity was neutropenia (NCI-CTC grade 1–2/3/4) which developed in 0/0/56% of patients (I), 11/0/56% of patients (II), and 20/20/50% of patients (III), respectively. At least 50% reduction in tumor volume was oberved in 14 patients. Five patients (18%) achieved a pathologic complete response (3 patients in cohort I, 2 patients in cohort II). Conclusions: O up to a dose of 7 mg/kg/d given as a 24 hour infusion on day 1–7 can be safely administered in combination with standard TAC on day 5 as NST in patients with PBC. The preliminary efficacy warrants further evaluation of this combination in a randomised trial. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Rom
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - B. Schlehe
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - F. Marmé
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - F. Schuetz
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - M. Eichbaum
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - H. Sinn
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - T. Buechele
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - C. Sohn
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - G. von Minckwitz
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| | - A. Schneeweiss
- University Womens Hospital of Heidelberg, Heidelberg, Germany; University of Heidelberg, Heidelberg, Germany; Aventis Pharma Deutschland GmbH, Bad Soden, Germany; German Breast Group, Neu Isenburg, Germany
| |
Collapse
|
41
|
Schuetz F, Sachsenweger C, Rom J, Schneeweiss A, Schirrmacher V, Beckhove P, Sohn C. Interactions of breast cancer cells and tumorantigen-reactive T-cells derived from bone marrow. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.13517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13517 Breast cancer is an immunogenic tumor which is usually recognized by the cellular immunosystem via tumor-associated antigens (TAA) presented by antigen-presenting cells like dendritic cells. Although we were able to find tumorantigen-reactive CD8+CD45R0+ T-memory cells (TMC) in the bone marrow of 67% of primary breast cancer patients by using interferon-?-ELISPOT-analysis there seem to be a minority of non-responers. In comparison to classic tumor characteristics non-responders can be find more often in non-differentiated, hormone-receptor negative tumors. In a phase-1 trial of a cellular immunotherapy with reactivated tumorantigen-reactive autologous TMC derived from bone marrow we measured CD4+ T-cell (TC) responses in stimulation cultures ex vivo to examine whether there are other immunological answers in non-responder. TC were activated by dendritic cells pulsed with TAA from MCF-7 lysate under IL-2 co-stimulation. We were able to show that next to a classic TH1-response with high levels of IFN-a there seems to exist TH2-responses mediated by high levels of TGF-β1 and low levels of IFN-a. The relation of both cytokines was directly related to the detection of tumorantigen-reactive TC and to tumor grading. Multiplex-cytokine analysis was able to confirm these findings. Additionally there seems to be an important impact of regulatory TC in responders as well as in non-responders. In patients with tumorantigen-reactive TC a combined active and passive vaccination therapy was done. These results may play an important role in further active and passive vaccination strategies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Schuetz
- University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - C. Sachsenweger
- University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - J. Rom
- University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - A. Schneeweiss
- University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - V. Schirrmacher
- University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - P. Beckhove
- University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - C. Sohn
- University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| |
Collapse
|
42
|
Schütz F, Beckhove P, Feuerer M, Schneeweiss A, Rom J, Schirrmacher V, Sohn C. Interaktionen zwischen Tumorantigen-reaktiven T-Zellen des Knochenmarks und Tumorzellen bei Patientinnen mit Mammakarzinom. Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-924673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
43
|
Schuetz F, Rom J, Ehlert K, Schirrmacher V, Schneeweiss A, Sohn C, Beckhove P. Immunological effects after an adoptive cellular immunotherapy with reactivated autologous memory T-Cells from bone marrow. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.12502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12502 Tumor-reactive CD4 and CD8 memory T cells (MTC) can be found in bone marrow (BM) of the majority of primary and metastatic breast cancer patients. In xenotransplant mouse models these cells, upon specific re-activation ex vivo, mediated efficient rejection of autologous breast tumors suggesting that the polyclonal natural MTC repertoire possesses therapeutic potential. In order to clinically exploit these anti-tumor capacities we treated 11 advanced metastasized breast cancer patients with autologous, tumor-reactive, reactivated MTC of BM in a phase-1 trial. Activation of T cells was done by MCF-7 lysate pulsed dendritic cells (DC). After reactivation both, T cells and pulsed DC were injected once intravenously. Peripheral blood was drawn on day 0, 1, 7, 14, 28. BM-re-aspiration was done on day 28 and 84. While TAA-reactive memory T cells were absent in the peripheral blood (PB) before therapy, 5 from 11 patients (=responders) showed TAA-specific PB T cell reactivity 7 days after therapeutic cell application suggesting a massive proliferation and mobilization into the blood of TAA-reactive T cells in these patients. A comparison of responders to adoptive cellular immunotherapy with non-responders revealed differences in the numbers of therapeutic cells that could be generated ex vivo and in the decreased frequency of tumor-reactive MTC in responders’ BM on days 28 and 84 which could be expained by a mobilization due to in situ activation by co-transferred DCs or due to local or systemic cytokine signals by transferred, activated T lymphocytes. Such effect might have contributed to the high numbers of circulating TAA-reactive T cells observed 7 days after the transfer. Furthermore we observed different concentrations of IL-4, IL-10, TNF-α, and INF-γ in PB and BM between the two groups leading to the hypothesis of a polarization in T cell responses (T1 type in responders vs T2 type in non-responders). No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Schuetz
- University of Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - J. Rom
- University of Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - K. Ehlert
- University of Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - V. Schirrmacher
- University of Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - A. Schneeweiss
- University of Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - C. Sohn
- University of Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| | - P. Beckhove
- University of Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany
| |
Collapse
|
44
|
Fersis N, Deckwart V, Leitz A, Weber M, Rom J, Böcher O, Albert WH, Bastert G, Sohn C, Kaul S. Molecular profiling of circulating tumor cells in the peripheral blood of patients with primary and metastatic breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20033 Background: The purpose of this study was detection and expression profiling of circulating tumor cells (CTC) in breast cancer patients. Methods: Two separate probes of 5 mL peripheral EDTA-blood from patients with primary breast cancer (n=167) and metastatic disease (n=111) were used for immunomagnetic tumor cell selection. Targets for preanalytical enrichment were the antigens EpCAM and MUC-1. Separated cells were lysed and used for mRNA isolation and c-DNA synthesis. The breast carcinoma-associated transcripts EpCAM, MUC-1, HER-2, claudin7, cytokeratin 19, mammaglobin 1, prostate-specific ets factor (PSE) and survivin were amplified by three separate multiplex RT-PCR reactions. Amplicons were analysed by capillary electrophoresis with the Agilent Bioanalyzer 2100. Specificity of the RT-PCR was confirmed by examination of blood of healthy donors. Results: Sensitivity for every single transcript was adjusted to 2 tumor cells per 5 ml blood. Tumor-associated transcripts were detected in 31 of of 167 (18.5%) patients with primary breast cancer and in 46 of 111 (41%) patients with metastatic disease. The marker with the highest incidence in both groups was MUC-1, with a positivity rate of 81%. Tumor-associated transcripts were heterogenouosly expressed, however multiple markers were identified in more than 50% of the positive samples. Conclusion: Using a combination of preanalytical immunomagnetic tumor cell enrichment followed by a multigen RT-PCR approach we describe a sensitive detection system for breast carcinoma cells. In this study a panel of 8 genes overexpressed at high levels in metastatic breast cancer was selected for the identification of disseminated tumor cells in the peripheral blood of breast cancer patients. HER-2, survivin as a unique member of the inhibitor of apotosis protein family, as well as PSE identified in circulating breast cancer cells may serve as prognostic indicators of tumor progression and could represent valid targets for new individualized therapeutic interventions. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Fersis
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - V. Deckwart
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - A. Leitz
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - M. Weber
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - J. Rom
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - O. Böcher
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - W. H. Albert
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - G. Bastert
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - C. Sohn
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| | - S. Kaul
- University of Heidelberg, Heidelberg, Germany; AdnaGen AG, Langenhagen, Germany; Klinik Bad Trissl, Bad Trissl, Germany
| |
Collapse
|
45
|
Abstract
OBJECTIVE To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas. METHODS c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation. RESULTS 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients. CONCLUSIONS While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.
Collapse
MESH Headings
- Adenocarcinoma/chemistry
- Adenocarcinoma/genetics
- Adult
- Aged
- Aged, 80 and over
- Breast Neoplasms/chemistry
- Breast Neoplasms/genetics
- Carcinoma, Ductal, Breast/chemistry
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Lobular/chemistry
- Carcinoma, Lobular/genetics
- Female
- Gene Amplification
- Genes, myc
- Genes, p53
- Humans
- Immunohistochemistry/methods
- In Situ Hybridization, Fluorescence
- Lymphatic Metastasis
- Middle Aged
- Neoplasm Recurrence, Local/chemistry
- Neoplasm Recurrence, Local/genetics
- Proportional Hazards Models
- Receptors, Estrogen/analysis
- Receptors, Progesterone/analysis
Collapse
Affiliation(s)
- S Aulmann
- Department of Pathology, University of Heidelberg, Heidelberg, Germany.
| | | | | | | | | | | |
Collapse
|
46
|
Rom J, Montserrat S, Samsó JM, Ballús C. [Psychotropic effect of Tegretol. Experimental clinical study]. Arch Neurobiol (Madr) 1967; 30:397-415. [PMID: 5618883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|